AstraZeneca’s (AZN) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank reissued their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research note issued to investors on Tuesday,Digital Look reports. Berenberg Bank currently has a £160 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on AZN. Citigroup downgraded AstraZeneca to a “buy” rating in a research report on Friday, July 10th. Jefferies Financial Group reissued a “buy” rating and set a £180 price objective on shares of AstraZeneca in a research report on Friday, June 26th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating and set a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of £153.

Get AstraZeneca alerts:

Read Our Latest Stock Analysis on AstraZeneca

AstraZeneca Stock Performance

Shares of AZN opened at £127.20 on Tuesday. The company has a market capitalization of £197.27 billion, a PE ratio of 19.16, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a one year low of £107.84 and a one year high of £157.32. The company’s fifty day moving average price is £134.30 and its 200 day moving average price is £140.33.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Further Reading

• Five stocks we like better than AstraZeneca
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.